238 related articles for article (PubMed ID: 19495753)
1. A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.
Endo M; Miwa M; Ura M; Tanimura H; Taniguchi K; Miyazaki Y; Ohwada J; Tsukazaki M; Niizuma S; Murata T; Ozawa S; Suda H; Ogawa K; Nanba E; Nagao S; Shimma N; Yamada-Okabe H
Cancer Chemother Pharmacol; 2010 Jan; 65(2):363-71. PubMed ID: 19495753
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog.
Ohwada J; Ozawa S; Kohchi M; Fukuda H; Murasaki C; Suda H; Murata T; Niizuma S; Tsukazaki M; Ori K; Yoshinari K; Itezono Y; Endo M; Ura M; Tanimura H; Miyazaki Y; Kawashima A; Nagao S; Namba E; Ogawa K; Kobayashi K; Okabe H; Umeda I; Shimma N
Bioorg Med Chem Lett; 2009 May; 19(10):2772-6. PubMed ID: 19362835
[TBL] [Abstract][Full Text] [Related]
3. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
[TBL] [Abstract][Full Text] [Related]
4. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
[TBL] [Abstract][Full Text] [Related]
5. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
Inoue Y; Ikegami Y; Sano K; Suzuki T; Yoshida H; Nakamura Y; Nakagawa H; Ishikawa T
Chemotherapy; 2013; 59(4):260-72. PubMed ID: 24457609
[TBL] [Abstract][Full Text] [Related]
10. BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.
Adams DJ; Waud WR; Wani MC; Manikumar G; Flowers JL; Driscoll TA; Morgan LR
Cancer Chemother Pharmacol; 2011 Apr; 67(4):855-65. PubMed ID: 20567829
[TBL] [Abstract][Full Text] [Related]
11. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Maliepaard M; van Gastelen MA; Tohgo A; Hausheer FH; van Waardenburg RC; de Jong LA; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2001 Apr; 7(4):935-41. PubMed ID: 11309344
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional supramolecular prodrug vesicles constructed from a camptothecin derivative with a water-soluble pillar[5]arene for cancer diagnosis and therapy.
Sun G; He Z; Hao M; Xu Z; Hu XY; Zhu JJ; Wang L
Chem Commun (Camb); 2019 Sep; 55(73):10892-10895. PubMed ID: 31436766
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
14. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.
Anthoney DA; Naik J; Macpherson IR; Crawford D; Hartley JM; Hartley JA; Saito T; Abe M; Jones K; Miwa M; Twelves C; Evans TR
BMC Cancer; 2012 Nov; 12():536. PubMed ID: 23170896
[TBL] [Abstract][Full Text] [Related]
16. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel 10-substituted-7-ethyl-10-hydroxycamptothecin (SN-38) prodrugs.
Zhou M; Liu M; He X; Yu H; Wu D; Yao Y; Fan S; Zhang P; Shi W; Zhong B
Molecules; 2014 Nov; 19(12):19718-31. PubMed ID: 25438082
[TBL] [Abstract][Full Text] [Related]
18. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
19. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Su Y; Lee SH; Sinko PJ
Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
